Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Market price (% of par)
-
77.74%
-
Total 13F principal
-
$391,549,000
-
Principal change
-
+$13,326,000
-
Total reported market value
-
$304,651,000
-
Number of holders
-
49
-
Value change
-
-$475,345
-
Number of buys
-
26
-
Number of sells
-
17
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q3 2017
As of 30 Sep 2017,
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 was held by
49 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$391,549,000
in principal (par value) of the bond.
The largest 10 bondholders included
HIGHFIELDS CAPITAL MANAGEMENT LP, DEERFIELD MANAGEMENT CO, Allianz Asset Management GmbH, ADVENT CAPITAL MANAGEMENT /DE/, AMERIPRISE FINANCIAL INC, MACKAY SHIELDS LLC, CITADEL ADVISORS LLC, JPMORGAN CHASE & CO, STATE STREET CORP, and Polar Capital LLP.
This page lists
49
institutional bondholders reporting positions
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.